A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 94 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 12th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 77 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 3 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
17 studies in Dermatitis, Atopic by Incyte Corporation: 2 open now, 3 under way, 1 of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 3, and was the 13th registered.
Incyte Corporation’s Dermatitis, Atopic studies by the year they started, since 2017.
1 of the studies testing ruxolitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661979Wake Forest University Health SciencesOpzelura Experience Study | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 17 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concurrent conditions and history of other diseases as follows:
Any of the following clinical laboratory test results at screening:
Liver function tests:
Use of any of the following treatments within the indicated before Day 1:
Note: COVID-19 vaccination is allowed.
Note: Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Drug: Ruxolitinib Cream
Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Drug: Vehicle Cream
Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 24 during the Vehicle Control Extension (VCE) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
Drug: Ruxolitinib Cream
Participants who applied vehicle cream during the VC Period, continued applying vehicle cream as a thin film twice daily (BID) from Weeks 8 to 24 during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved. Participants will be eligible to enter the ruxolitinib 1.5% cream open-label escape arm as defined in the protocol.
Drug: Vehicle Cream
Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film twice daily (BID) during the VCE Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
Drug: Ruxolitinib Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Also known as: INCB018424 Phosphate Cream
Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
Time frame: Baseline; Week 8
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
Time frame: Baseline; Week 8
Percentage of Participants Achieving a ≥4-point Improvement in Itch Numeric Rating Scale (NRS) Score (ITCH4) From Baseline to Week 8
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
Time frame: Baseline; Week 8
Percentage of Participants Achieving ITCH4 From Baseline to Days 2, 3, and 7
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
Time frame: Baseline; Days 2, 3, and 7
Vehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.
Time frame: up to Week 12
Vehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.
Time frame: up to 20 weeks (from Week 8 to Week 24 plus 30 days)
VCE Escape Arm: Number of Participants With Any TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.
Time frame: up to 150 days
VC Period: Number of Participants With Any ≥Grade 3 TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to Week 12
VCE DB Period: Number of Participants With Any ≥Grade 3 TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 20 weeks (from Week 8 to Week 24 plus 30 days)
VCE Escape Arm: Number of Participants With Any ≥Grade 3 TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to 150 days
Double-blind Treatment Period: Percentage of Participants Achieving EASI75 From Baseline at Weeks 2, 4, 12, 16, 20, and 24
EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
Time frame: Baseline; Weeks 2, 4, 12, 16, 20, and 24
VCE Escape Arm: Percentage of Participants Achieving EASI75 From Baseline at Weeks 12, 16, 20, and 24
EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Double-blind Treatment Period: Percentage of Participants With IGA-TS From Baseline at Each Postbaseline Visit Except Week 8
IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
Time frame: Baseline; Weeks 2, 4, 12, 16, 20, and 24
VCE Escape Arm: Percentage of Participants With IGA-TS From Baseline at Weeks 12, 16, 20, and 24
IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Percentage of Participants Achieving ITCH4 From Baseline to Weeks 2 and 4
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
Time frame: Baseline; Weeks 2 and 4
Time to Achieve ITCH4 During the VC Period
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
Time frame: up to Week 8
Time to Achieve ITCH2 During the VC Period
ITCH2 is defined as achieving a ≥2-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
Time frame: up to Week 8
Change From Baseline (Pre-application) in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-initial Dose on Day 1
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Day 1
Percentage of Participants Achieving at Least a 2-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
Time frame: Baseline; Day 1
Percentage of Participants Achieving at Least a 4-point Decrease From Baseline in Current Itch NRS Score at 5, 15, 30, 45, and 60 Minutes and 2, 4, and 6 Hours Post-Initial Dose on Day 1
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
Time frame: Baseline; Day 1
Double-blind Treatment Period: Percentage of Participants Achieving EASI50 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24
EASI50 was defined as achieving a ≥50% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
Double-blind Treatment Period: Percentage of Participants With EASI90 From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24
EASI90 was defined as achieving a ≥90% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
Double-blind Treatment Period: Percentage of Participants Achieving Both EASI75 and IGA-TS at Weeks 2, 4, 8, 12, 16, 20, and 24
EASI75=a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system grades the physical signs of AD to provide a measure of severity (range=0-72). EASI disease severity strata: 0 = clear; 0.1-1.0 = almost clear; 1.1-7.0 = mild; 7.1-21.0 = moderate; 21.1-50.0 = severe; 50.1 to 72.0 = very severe. IGA-TS = an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
Time frame: Baseline; Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline for Atopic Dermatitis-affected %Body Surface Area (BSA) at Weeks 2, 4, and 8 of the Double-blind Treatment Period
BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline for Atopic Dermatitis-affected %BSA at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline for the EASI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline for the EASI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline for the SCORing Atopic Dermatitis (SCORAD) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM25.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline for the SCORAD Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM27.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline for Itch NRS Score at Days 1 Through 56 (8 Weeks)
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Days 1 through 56 (8 weeks)
Change From Baseline for Skin Pain NRS Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Skin Pain NRS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Time to Open-label Escape Arm
The study allowed participants to move to an open-label ruxolitinib 1.5% escape arm if they had not met EASI50 (50% improvement in the EASI score from baseline at 2 consecutive visits at least 1 week apart) at Week 8 (end of the double-blind, vehicle-controlled period and the start of the vehicle-controlled extension, double-blind period) or if they lost EASI50 response during the vehicle-controlled extension, double-blind period. Participants who were moved to the open-label ruxolitinib 1.5% escape arm without meeting the criteria were censored.
Time frame: up to 16 weeks (from Week 8 to Week 24)
Percentage of Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score, ≥4, BSA ≥10%, and Dermatology Life Quality Index (DLQI) Score >10
Only data in the DB treatment period were included in the analysis.
Time frame: up to 16 weeks (from Week 8 to Week 24)
Time to Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score ≥4, BSA ≥10%, and DLQI Score >10
Only data in the DB treatment period were included in the analysis.
Time frame: up to 16 weeks (from Week 8 to Week 24)
Percentage of Participants Who Experienced a Relapse After Study Treatment Discontinuation
Relapse was assessed during the 30-day Safety Follow-up Period for participants who had an EASI75 response from baseline at the end of the VCE DB period at Week 24. Participants who experienced a relapse were those among EASI75 responders who were on study treatment at Week 24 who met relapse criteria (loss of EASI50 from baseline) at the safety follow-up visit.
Time frame: up to 30 days following Week 24
Time to First Retreatment During the VCE DB Period
Time to first retreatment following the participant's first lesion clearance during the VCE DB period was evaluated in participants who had at least 1 occurrence of lesion clearance.
Time frame: up to 16 weeks (from Week 8 to Week 24)
Percentage of Time Off Study Treatment Due to Lesion Clearance During the VCE DB Period
The percentage of time off study treatment was calculated as the total days off study treatment due to lesion clearance divided by the total days between two visits per participant.
Time frame: from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
Percentage of Time on Study Treatment During the VCE DB Period
The percentage of time on study treatment was calculated as the total days intended on study treatment divided by the total days between two visits per participant.
Time frame: from Week 8 to Week 12; from Week 12 to Week 16; from Week 16 to Week 20; from Week 20 to Week 24
Double-blind Treatment Period: Percentage of Participants Who Achieved a ≥4-point Improvement in Dermatology Life Quality Index (DLQI) From Baseline at Weeks 2, 4, 8, 12, 16, 20, and 24
The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect.
Time frame: Baseline; Weeks 2, 4, 12, 16, 20, and 24
Change From Baseline in the DLQI Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline in the DLQI Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline in the Patient-oriented Eczema Measure (POEM) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with total scores ranging from 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline in the POEM Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with a range in total score of 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline in the EQ-5D-5L Visual Analog Scale Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Score at Weeks 2, 4, and 8 of the Double-blind Treatment Period
The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline in the HADS Score at Weeks 12, 16, 20, and 24 of the Double-blind Treatment Period
The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 2, 4, and 8
The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline in the PROMIS Short Form - Sleep-Related Impairment (8a: 7-day Recall) Score at Weeks 12, 16, 20, and 24
The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 2, 4, and 8
The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 2, 4, and 8
Change From Baseline in the PROMIS Short Form - Sleep Disturbance (8b: 7-day Recall) Score at Weeks 12, 16, 20, and 24
The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 12, 16, 20, and 24
Change From Baseline in the Work Productivity and Activity Impairment Questionairre-Atopic Dermatitis (WPAI-AD) Score at Weeks 8 and 24
The WPAI-AD questionnaire is a validated 6-item instrument that measures the effect of overall health and specific symptoms on productivity at work and regular activities outside of it during the past 7 days. The WPAI outcomes are expressed as impairment percentages (0% to 100% for all outcomes; higher number indicate greater impairment and less productivity \[i.e., worse outcomes\]): Questions: 1 = currently employed; 2 = hours missed due to AD; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree AD-affected productivity while working; 6 = degree AD-affected regular activities. Scores: multiply scores by 100 to express in percentages: percent work time missed due to AD: Q2 / (Q2 + Q4); percent impairment while working due to AD: Q5 / 10; percent overall work impairment due to AD: Q2 / (Q2 + Q4) + (\[1 - (Q2 / (Q2+Q4)\] × \[Q5/10\]); percent activity impairment due to AD: Q6 / 10. Change from baseline was calculated as the post-baseline value minus the baseline value.
Time frame: Baseline; Weeks 8 and 24
| Milestone | Vehicle Cream | Ruxolitinib 1.5% Cream | Vehicle Cream to Ruxolitinib 1.5% Cream | Ruxolitinib 1.5% Cream to Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Started | 81 | 160 | 0 | 0 |
| Entered escape arm at week 8 | 40 | 32 | 0 | 0 |
| Completed | 60 | 154 | 0 | 0 |
| Not completed | 21 | 6 | 0 | 0 |
| Withdrew: Adverse event | 7 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 1 | 0 | 0 |
| Withdrew: Unable to comply with study visit requirements | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 0 |
| Milestone | Vehicle Cream | Ruxolitinib 1.5% Cream | Vehicle Cream to Ruxolitinib 1.5% Cream | Ruxolitinib 1.5% Cream to Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Started | 20 | 121 | 0 | 0 |
| Entered escape arm during vce db period | 6 | 14 | 0 | 0 |
| Completed | 19 | 114 | 0 | 0 |
| Not completed | 1 | 7 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Milestone | Vehicle Cream | Ruxolitinib 1.5% Cream | Vehicle Cream to Ruxolitinib 1.5% Cream | Ruxolitinib 1.5% Cream to Ruxolitinib 1.5% Cream |
|---|---|---|---|---|
| Started | 0 | 0 | 46 | 46 |
| Completed | 0 | 0 | 41 | 38 |
| Not completed | 0 | 0 | 5 | 8 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Inadvertently enrolled in escape arm | 0 | 0 | 0 | 1 |
EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8 | 18.5 (10.8 to 28.7) | 70.0 (62.3 to 77.0) |
IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8 | 13.6 (7.0 to 23.0) | 61.3 (53.2 to 68.8) |
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Percentage of Participants Achieving a ≥4-point Improvement in Itch Numeric Rating Scale (NRS) Score (ITCH4) From Baseline to Week 8 | 19.8 (11.7 to 30.1) | 62.5 (54.5 to 70.0) |
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Day 2 | 13.67 | 29.75 |
| Day 3 | 9.88 | 35.09 |
| Day 7 | 13.86 | 51.20 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.
| Participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Vehicle-controlled (VC) Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 29 | 56 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.
| Participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Vehicle-controlled Extension Double-blind (VCE DB) Period: Number of Participants With Any TEAE | 5 | 43 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit.
| Participants | Vehicle Cream to Ruxolitinib 1.5% Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| VCE Escape Arm: Number of Participants With Any TEAE | 14 | 11 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| VC Period: Number of Participants With Any ≥Grade 3 TEAE | 1 | 5 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| VCE DB Period: Number of Participants With Any ≥Grade 3 TEAE | 0 | 1 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of study cream and no later than 30 days after the Week 24 or early termination visit. The severity of TEAEs was assessed using CTCAE v5.0 Grades 1-5. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| Participants | Vehicle Cream to Ruxolitinib 1.5% Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| VCE Escape Arm: Number of Participants With Any ≥Grade 3 TEAE | 0 | 0 |
EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 2 | 3.7 (0.8 to 10.4) | 43.8 (35.9 to 51.8) |
| Week 4 | 12.3 (6.1 to 21.5) | 61.3 (53.2 to 68.8) |
| Week 12 | 88.9 (65.3 to 98.6) | 81.5 (73.4 to 88.0) |
| Week 16 | 78.6 (49.2 to 95.3) | 85.6 (77.6 to 91.5) |
| Week 20 | 71.4 (41.9 to 91.6) | 85.7 (77.5 to 91.8) |
| Week 24 | 84.6 (54.6 to 98.1) | 84.5 (76.0 to 90.9) |
EASI75 was defined as achieving a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
| percentage of participants | Vehicle Cream to Ruxolitinib 1.5% Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 12 | 50.0 (33.4 to 66.6) | 37.9 (20.7 to 57.7) |
| Week 16 | 64.9 (47.5 to 79.8) | 44.8 (26.4 to 64.3) |
| Week 20 | 70.3 (53.0 to 84.1) | 57.1 (37.2 to 75.5) |
| Week 24 | 70.3 (53.0 to 84.1) | 60.7 (40.6 to 78.5) |
IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 2 | 2.5 (0.3 to 8.6) | 29.4 (22.4 to 37.1) |
| Week 4 | 9.9 (4.4 to 18.5) | 48.8 (40.8 to 56.8) |
| Week 12 | 61.1 (35.7 to 82.7) | 65.5 (56.3 to 74.0) |
| Week 16 | 71.4 (41.9 to 91.6) | 64.9 (55.2 to 73.7) |
| Week 20 | 64.3 (35.1 to 87.2) | 68.6 (58.8 to 77.3) |
| Week 24 | 69.2 (38.6 to 90.9) | 70.9 (61.1 to 79.4) |
IGA-TS was defined as achieving an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
| percentage of participants | Vehicle Cream to Ruxolitinib 1.5% Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 12 | 39.5 (24.0 to 56.6) | 34.5 (17.9 to 54.3) |
| Week 16 | 51.4 (34.4 to 68.1) | 37.9 (20.7 to 57.7) |
| Week 20 | 59.5 (42.1 to 75.2) | 46.4 (27.5 to 66.1) |
| Week 24 | 62.2 (44.8 to 77.5) | 46.4 (27.5 to 66.1) |
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 2 | 9.9 (4.4 to 18.5) | 47.5 (39.6 to 55.5) |
| Week 4 | 17.3 (9.8 to 27.3) | 56.3 (48.2 to 64.1) |
ITCH4 is defined as achieving a ≥4-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
| days | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Time to Achieve ITCH4 During the VC Period | 46.0 (23.00 to NA) | 5.0 (4.00 to 7.00) |
ITCH2 is defined as achieving a ≥2-point improvement from baseline in Itch NRS score. The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
| days | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Time to Achieve ITCH2 During the VC Period | 6.0 (3.00 to 14.00) | 2.0 (1.00 to 2.00) |
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 7.06 ± 1.691 | 7.13 ± 1.869 |
| Change from baseline at 5 minutes post-initial dose | -0.52 ± 1.441 | -0.70 ± 1.698 |
| Change from baseline at 15 minutes post-initial dose | -0.92 ± 1.622 | -1.54 ± 1.987 |
| Change from baseline at 30 minutes post-initial dose | -1.31 ± 1.740 | -2.09 ± 2.390 |
| Change from baseline at 45 minutes post-initial dose | -1.76 ± 1.946 | -2.35 ± 2.436 |
| Change from baseline at 60 minutes post-initial dose | -2.13 ± 2.056 | -2.56 ± 2.606 |
| Change from baseline at 2 hours post-initial dose | -2.13 ± 2.117 | -2.56 ± 2.473 |
| Change from baseline at 4 hours post-initial dose | -1.68 ± 1.918 | -2.67 ± 2.483 |
| Change from baseline at 6 hours post-initial dose | -1.41 ± 1.646 | -2.47 ± 2.390 |
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| 5 minutes post-initial dose | 13.0 (6.1 to 23.3) | 19.7 (13.4 to 27.4) |
| 15 minutes post-initial dose | 21.9 (13.1 to 33.1) | 35.3 (27.3 to 43.8) |
| 30 minutes post-initial dose | 32.0 (21.7 to 43.8) | 49.3 (40.7 to 57.9) |
| 45 minutes post-initial dose | 41.7 (30.2 to 53.9) | 55.6 (47.1 to 64.0) |
| 60 minutes post-initial dose | 52.0 (40.2 to 63.7) | 59.2 (50.6 to 67.3) |
| 2 hours post-initial dose | 46.8 (35.3 to 58.5) | 60.1 (51.5 to 68.4) |
| 4 hours post-initial dose | 43.7 (31.9 to 56.0) | 59.7 (51.1 to 67.9) |
| 6 hours post-initial dose | 38.6 (27.2 to 51.0) | 58.4 (49.2 to 67.1) |
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| 5 minutes post-initial dose | 7.6 (2.5 to 16.8) | 6.0 (2.6 to 11.4) |
| 15 minutes post-initial dose | 7.1 (2.4 to 15.9) | 17.5 (11.6 to 24.9) |
| 30 minutes post-initial dose | 13.9 (6.9 to 24.1) | 24.8 (17.8 to 32.9) |
| 45 minutes post-initial dose | 20.0 (11.4 to 31.3) | 27.3 (20.1 to 35.5) |
| 60 minutes post-initial dose | 27.8 (17.9 to 39.6) | 31.7 (24.0 to 40.1) |
| 2 hours post-initial dose | 23.0 (14.0 to 34.2) | 30.1 (22.6 to 38.6) |
| 4 hours post-initial dose | 14.7 (7.3 to 25.4) | 33.8 (25.9 to 42.4) |
| 6 hours post-initial dose | 10.3 (4.2 to 20.1) | 29.5 (21.6 to 38.4) |
EASI50 was defined as achieving a ≥50% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 2 | 11.1 (5.2 to 20.0) | 69.4 (61.6 to 76.4) |
| Week 4 | 25.9 (16.8 to 36.9) | 79.4 (72.3 to 85.4) |
| Week 8 | 24.7 (15.8 to 35.5) | 80.6 (73.6 to 86.4) |
| Week 12 | 100.0 (81.5 to 100.0) | 89.1 (82.0 to 94.1) |
| Week 16 | 100.0 (76.8 to 100.0) | 94.6 (88.6 to 98.0) |
| Week 20 | 92.9 (66.1 to 99.8) | 94.3 (88.0 to 97.9) |
| Week 24 | 100.0 (75.3 to 100.0) | 96.1 (90.4 to 98.9) |
EASI90 was defined as achieving a ≥90% improvement in the EASI score compared to the baseline score. The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 2 | 1.2 (0.0 to 6.7) | 21.9 (15.7 to 29.1) |
| Week 4 | 4.9 (1.4 to 12.2) | 41.3 (33.5 to 49.3) |
| Week 8 | 8.6 (3.5 to 17.0) | 56.9 (48.8 to 64.7) |
| Week 12 | 50.0 (26.0 to 74.0) | 53.8 (44.4 to 63.0) |
| Week 16 | 57.1 (28.9 to 82.3) | 64.0 (54.3 to 72.9) |
| Week 20 | 57.1 (28.9 to 82.3) | 57.1 (47.1 to 66.8) |
| Week 24 | 46.2 (19.2 to 74.9) | 66.0 (56.0 to 75.1) |
EASI75=a ≥75% improvement in the EASI score compared to the baseline score. The EASI scoring system grades the physical signs of AD to provide a measure of severity (range=0-72). EASI disease severity strata: 0 = clear; 0.1-1.0 = almost clear; 1.1-7.0 = mild; 7.1-21.0 = moderate; 21.1-50.0 = severe; 50.1 to 72.0 = very severe. IGA-TS = an IGA score of 0 or 1 with a ≥2-grade improvement from baseline. The IGA is an overall eczema severity rating on a 0 to 4 scale. 0: clear; no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1: almost clear; may be trace faint pink erythema, with almost no induration/papulation, and no oozing/crusting. 2: mild; may be faint pink erythema, with mild induration/papulation and no oozing/crusting. 3: moderate; may be pink-red erythema with moderate induration/papulation and may be some oozing/crusting. 4: severe; may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 2 | 2.5 (0.3 to 8.6) | 26.3 (19.6 to 33.8) |
| Week 4 | 9.9 (4.4 to 18.5) | 46.3 (38.3 to 54.3) |
| Week 8 | 13.6 (7.0 to 23.0) | 59.4 (51.3 to 67.1) |
| Week 12 | 61.1 (35.7 to 82.7) | 63.0 (53.7 to 71.7) |
| Week 16 | 71.4 (41.9 to 91.6) | 63.1 (53.4 to 72.0) |
| Week 20 | 64.3 (35.1 to 87.2) | 66.7 (56.8 to 75.6) |
| Week 24 | 69.2 (38.6 to 90.9) | 69.9 (60.1 to 78.5) |
BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.
| percentage of BSA | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -1.04 ± 0.622 | -6.96 ± 0.417 |
| Change from baseline at Week 4 | -2.36 ± 0.683 | -9.30 ± 0.455 |
| Change from baseline at Week 8 | -4.22 ± 0.671 | -10.84 ± 0.435 |
BSA assessment was approximated to the nearest 0.1% using the handprint (Palmar) method as a guide. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits, with fingers tucked together and thumb tucked to the side) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from baseline was calculated as the post-baseline value minus the baseline value.
| percentage of BSA | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 15.43 ± 2.947 | 14.98 ± 3.068 |
| Change from baseline at Week 12 | -11.28 ± 3.230 | -11.79 ± 4.725 |
| Change from baseline at Week 16 | -11.74 ± 4.010 | -12.22 ± 4.109 |
| Change from baseline at Week 20 | -11.26 ± 4.309 | -12.04 ± 4.559 |
| Change from baseline at Week 24 | -11.83 ± 3.255 | -12.50 ± 4.691 |
The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -1.50 ± 0.509 | -7.59 ± 0.341 |
| Change from baseline at Week 4 | -3.14 ± 0.509 | -9.24 ± 0.340 |
| Change from baseline at Week 8 | -4.49 ± 0.508 | -9.80 ± 0.330 |
The EASI scoring system is a validated scoring system that grades the physical signs of atopic dermatitis (AD) to provide a measure of AD severity (ranging from 0 to 72). The disease severity strata for the EASI are: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 12.84 ± 3.634 | 12.50 ± 4.280 |
| Change from baseline at Week 12 | -10.33 ± 3.999 | -10.17 ± 4.575 |
| Change from baseline at Week 16 | -9.38 ± 2.580 | -10.79 ± 4.176 |
| Change from baseline at Week 20 | -9.12 ± 3.120 | -10.86 ± 3.861 |
| Change from baseline at Week 24 | -9.63 ± 2.700 | -10.93 ± 4.020 |
The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM25.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -6.12 ± 1.662 | -26.08 ± 1.115 |
| Change from baseline at Week 4 | -11.28 ± 1.769 | -32.68 ± 1.181 |
| Change from baseline at Week 8 | -14.71 ± 1.942 | -35.79 ± 1.262 |
The SCORAD assesses the extent and severity (intensity) of eczema. To determine extent, the rule of 9 or handprint method was used to calculate the eczema affected area (A) as a percentage of the whole body. Scores were added to give a possible maximum of 100%. To determine intensity, a representative area of eczema was selected. The intensity of redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification), dryness was assessed individually: none, 0; mild, 1; moderate, 2; severe, 3. Intensity scores were added together to give "B" (maximum score of 18). Subjective symptoms (itch and sleeplessness) were scored by the participant using a visual analog scale on which "0" was no itch (or no sleeplessness) and "10" was the worst imaginable itch (or sleeplessness). These scores were added to give "C" (maximum score of 20). The total score\[KM27.1\] (ranging from 0 to 103; a higher score indicates greater extent and severity) was calculated as: A/5 + 7B/2 + C.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 53.11 ± 10.429 | 53.90 ± 10.938 |
| Change from baseline at Week 12 | -29.80 ± 13.377 | -36.32 ± 14.801 |
| Change from baseline at Week 16 | -33.36 ± 14.448 | -38.14 ± 15.264 |
| Change from baseline at Week 20 | -32.29 ± 15.272 | -39.53 ± 14.092 |
| Change from baseline at Week 24 | -35.41 ± 12.494 | -39.08 ± 13.714 |
The Itch NRS is a once-daily patient-reported measure of itch intensity assessed using an 11-point scale (0 = no itch to 10 = worst imaginable itch) that best describes their worst level of itching in the past 24 hours. The Itch NRS score for baseline was determined by averaging the 7 daily NRS scores directly before Day 1 (Day -7 to Day -1). The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily NRS scores directly before the visit day. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Day 1 | -1.03 ± 0.244 | -1.80 ± 0.175 |
| Change from baseline at Day 2 | -0.99 ± 0.260 | -2.65 ± 0.186 |
| Change from baseline at Day 3 | -1.13 ± 0.263 | -2.97 ± 0.190 |
| Change from baseline at Day 4 | -1.18 ± 0.276 | -3.38 ± 0.191 |
| Change from baseline at Day 5 | -0.99 ± 0.272 | -3.52 ± 0.196 |
| Change from baseline at Day 6 | -0.94 ± 0.294 | -3.68 ± 0.208 |
| Change from baseline at Day 7 | -1.06 ± 0.275 | -3.77 ± 0.201 |
| Change from baseline at Day 8 | -1.15 ± 0.310 | -3.83 ± 0.212 |
| Change from baseline at Day 9 | -1.27 ± 0.307 | -3.90 ± 0.212 |
| Change from baseline at Day 10 | -1.22 ± 0.296 | -3.89 ± 0.215 |
| Change from baseline at Day 11 | -1.40 ± 0.324 | -4.18 ± 0.223 |
| Change from baseline at Day 12 | -1.27 ± 0.314 | -4.19 ± 0.222 |
| Change from baseline at Day 13 | -1.60 ± 0.333 | -4.33 ± 0.224 |
| Change from baseline at Day 14 | -1.40 ± 0.316 | -4.33 ± 0.217 |
| Change from baseline at Day 15 | -1.56 ± 0.329 | -4.47 ± 0.220 |
| Change from baseline at Day 16 | -1.59 ± 0.336 | -4.60 ± 0.222 |
| Change from baseline at Day 17 | -2.02 ± 0.339 | -4.52 ± 0.225 |
| Change from baseline at Day 18 | -1.87 ± 0.334 | -4.83 ± 0.221 |
| Change from baseline at Day 19 | -1.60 ± 0.321 | -4.65 ± 0.217 |
| Change from baseline at Day 20 | -1.92 ± 0.325 | -4.79 ± 0.216 |
| Change from baseline at Day 21 | -1.79 ± 0.325 | -4.68 ± 0.212 |
| Change from baseline at Day 22 | -1.89 ± 0.328 | -4.69 ± 0.218 |
| Change from baseline at Day 23 | -1.80 ± 0.350 | -4.62 ± 0.231 |
| Change from baseline at Day 24 | -2.00 ± 0.335 | -4.70 ± 0.218 |
| Change from baseline at Day 25 | -2.05 ± 0.358 | -4.78 ± 0.235 |
| Change from baseline at Day 26 | -2.05 ± 0.363 | -4.70 ± 0.237 |
| Change from baseline at Day 27 | -1.91 ± 0.352 | -4.74 ± 0.233 |
| Change from baseline at Day 28 | -2.05 ± 0.350 | -4.91 ± 0.229 |
| Change from baseline at Day 29 | -2.15 ± 0.361 | -4.93 ± 0.231 |
| Change from baseline at Day 30 | -2.34 ± 0.347 | -5.03 ± 0.225 |
| Change from baseline at Day 31 | -2.19 ± 0.347 | -4.99 ± 0.236 |
| Change from baseline at Day 32 | -2.32 ± 0.339 | -4.98 ± 0.229 |
| Change from baseline at Day 33 | -2.29 ± 0.370 | -5.10 ± 0.240 |
| Change from baseline at Day 34 | -2.54 ± 0.339 | -5.16 ± 0.233 |
| Change from baseline at Day 35 | -2.69 ± 0.389 | -4.90 ± 0.233 |
| Change from baseline at Day 36 | -2.56 ± 0.371 | -5.16 ± 0.245 |
| Change from baseline at Day 37 | -2.72 ± 0.379 | -4.99 ± 0.239 |
| Change from baseline at Day 38 | -2.39 ± 0.359 | -4.87 ± 0.234 |
| Change from baseline at Day 39 | -2.33 ± 0.359 | -4.99 ± 0.241 |
| Change from baseline at Day 40 | -2.16 ± 0.392 | -4.99 ± 0.237 |
| Change from baseline at Day 41 | -2.66 ± 0.395 | -5.03 ± 0.249 |
| Change from baseline at Day 42 | -2.34 ± 0.349 | -5.20 ± 0.226 |
| Change from baseline at Day 43 | -2.79 ± 0.373 | -5.23 ± 0.237 |
| Change from baseline at Day 44 | -2.84 ± 0.390 | -5.22 ± 0.236 |
| Change from baseline at Day 45 | -2.63 ± 0.351 | -5.17 ± 0.246 |
| Change from baseline at Day 46 | -2.60 ± 0.375 | -5.18 ± 0.242 |
| Change from baseline at Day 47 | -2.69 ± 0.373 | -5.26 ± 0.235 |
| Change from baseline at Day 48 | -2.38 ± 0.364 | -5.27 ± 0.229 |
| Change from baseline at Day 49 | -2.38 ± 0.379 | -5.17 ± 0.250 |
| Change from baseline at Day 50 | -2.63 ± 0.362 | -5.07 ± 0.235 |
| Change from baseline at Day 51 | -2.51 ± 0.424 | -5.05 ± 0.262 |
| Change from baseline at Day 52 | -2.27 ± 0.421 | -5.18 ± 0.248 |
| Change from baseline at Day 53 | -2.53 ± 0.385 | -5.28 ± 0.251 |
| Change from baseline at Day 54 | -2.89 ± 0.421 | -5.14 ± 0.250 |
| Change from baseline at Day 55 | -2.93 ± 0.426 | -5.26 ± 0.266 |
| Change from baseline at Day 56 | -2.84 ± 0.456 | -4.96 ± 0.284 |
The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -1.60 ± 0.278 | -4.20 ± 0.185 |
| Change from baseline at Week 4 | -2.08 ± 0.280 | -4.79 ± 0.186 |
| Change from baseline at Week 8 | -2.62 ± 0.304 | -5.12 ± 0.197 |
The Skin Pain NRS is a daily participant-reported measure (24-hour or 7-day recall) of the worst level of pain intensity from 0 (no pain) to 10 (worst pain imaginable). Participants were asked to rate the pain intensity by selecting a number that best describes the worst level of pain in the past 24 hours during the VC period and in the past 7 days during the VCE period.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 12 | 3.17 ± 2.834 | 1.97 ± 2.214 |
| Week 16 | 2.00 ± 2.602 | 2.03 ± 2.192 |
| Week 20 | 2.43 ± 2.441 | 1.58 ± 1.788 |
| Week 24 | 2.62 ± 2.022 | 1.62 ± 1.990 |
The study allowed participants to move to an open-label ruxolitinib 1.5% escape arm if they had not met EASI50 (50% improvement in the EASI score from baseline at 2 consecutive visits at least 1 week apart) at Week 8 (end of the double-blind, vehicle-controlled period and the start of the vehicle-controlled extension, double-blind period) or if they lost EASI50 response during the vehicle-controlled extension, double-blind period. Participants who were moved to the open-label ruxolitinib 1.5% escape arm without meeting the criteria were censored.
| days | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Time to Open-label Escape Arm | 1.0 (NA to NA) | NA (NA to NA) |
Only data in the DB treatment period were included in the analysis.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Percentage of Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score, ≥4, BSA ≥10%, and Dermatology Life Quality Index (DLQI) Score >10 | 14.8 | 3.8 |
Only data in the DB treatment period were included in the analysis.
| days | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Time to Participants in the VCE DB Period Concurrently Meeting All of the Following Criteria: IGA Score ≥3, EASI Score ≥16, Itch NRS Score ≥4, BSA ≥10%, and DLQI Score >10 | NA (NA to NA) | NA (NA to NA) |
Relapse was assessed during the 30-day Safety Follow-up Period for participants who had an EASI75 response from baseline at the end of the VCE DB period at Week 24. Participants who experienced a relapse were those among EASI75 responders who were on study treatment at Week 24 who met relapse criteria (loss of EASI50 from baseline) at the safety follow-up visit.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Percentage of Participants Who Experienced a Relapse After Study Treatment Discontinuation | 0.00 | 18.52 |
Time to first retreatment following the participant's first lesion clearance during the VCE DB period was evaluated in participants who had at least 1 occurrence of lesion clearance.
| days | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Time to First Retreatment During the VCE DB Period | 26.0 (2.00 to NA) | 5.0 (4.00 to 6.00) |
The percentage of time off study treatment was calculated as the total days off study treatment due to lesion clearance divided by the total days between two visits per participant.
| percentage of days | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 8 to Week 12 | 4.10 ± 14.041 | 15.83 ± 23.644 |
| Week 12 to Week 16 | 19.16 ± 38.275 | 17.86 ± 27.221 |
| Week 16 to Week 20 | 21.86 ± 41.707 | 22.72 ± 30.994 |
| Week 20 to Week 24 | 26.12 ± 38.323 | 24.29 ± 32.962 |
The percentage of time on study treatment was calculated as the total days intended on study treatment divided by the total days between two visits per participant.
| percentage of days | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 8 to Week 12 | 90.97 ± 18.729 | 79.28 ± 26.663 |
| Week 12 to Week 16 | 79.83 ± 37.797 | 76.43 ± 29.169 |
| Week 16 to Week 20 | 76.63 ± 41.362 | 72.46 ± 31.409 |
| Week 20 to Week 24 | 72.70 ± 38.905 | 71.25 ± 33.319 |
The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect.
| percentage of participants | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Week 2 | 67.1 (54.9 to 77.9) | 93.1 (88.0 to 96.5) |
| Week 4 | 70.6 (58.3 to 81.0) | 94.8 (90.0 to 97.7) |
| Week 8 | 77.6 (64.7 to 87.5) | 97.4 (93.4 to 99.3) |
| Week 12 | 88.9 (65.3 to 98.6) | 97.4 (92.6 to 99.5) |
| Week 16 | 100.0 (76.8 to 100.0) | 96.4 (91.0 to 99.0) |
| Week 20 | 100.0 (76.8 to 100.0) | 99.0 (94.8 to 100.0) |
| Week 24 | 84.6 (54.6 to 98.1) | 99.0 (94.7 to 100.0) |
The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -5.79 ± 0.709 | -12.66 ± 0.472 |
| Change from baseline at Week 4 | -7.67 ± 0.716 | -14.20 ± 0.478 |
| Change from baseline at Week 8 | -8.33 ± 0.692 | -15.13 ± 0.445 |
The DLQI is 10-question validated questionnaire measuring how much the skin problem has affected the participant over the previous 7 days. The questionnaire is analyzed under 6 headings: symptoms and feelings (Questions 1 and 2); daily activities (Questions 3 and 4); leisure (Questions 5 and 6); work and school (Question 7); personal relations (Questions 8 and 9); treatment (Question 10). The scoring of each question is: 3, very much; 2, a lot; 1, a little; 0, not at all; not relevant, 0; Question 7, "prevented work or studying," 3. The DLQI is calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. Total DLQI scores can be categorized as: 0-1, no effect; 2-5, small effect; 6-10, moderate effect; 11-20, very large effect; 21-30, extremely large effect. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 19.10 ± 5.176 | 19.31 ± 5.057 |
| Change from baseline at Week 12 | -14.11 ± 8.331 | -15.51 ± 6.307 |
| Change from baseline at Week 16 | -16.79 ± 7.138 | -15.95 ± 6.406 |
| Change from baseline at Week 20 | -16.43 ± 7.398 | -16.59 ± 5.988 |
| Change from baseline at Week 24 | -16.00 ± 8.963 | -16.28 ± 6.069 |
The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with total scores ranging from 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -4.48 ± 0.768 | -12.61 ± 0.517 |
| Change from baseline at Week 4 | -5.54 ± 0.748 | -14.22 ± 0.504 |
| Change from baseline at Week 8 | -6.62 ± 0.834 | -14.71 ± 0.543 |
The POEM is a 7-question quality-of-life assessment used for monitoring atopic eczema severity, focusing on the illness as experienced by the participant. The questionnaire asks how many days the participant has been bothered by various aspects of their skin condition during the past week. The response options and corresponding scoring questionnaires are: no days (0), 1 to 2 days (1), 3 to 4 days (2), 5 to 6 days (3), and every day (4), with a range in total score of 0 to 28. The meaning of POEM scores can be categorized as: 0 to 2 (clear/almost clear), 3 to 7 (mild eczema), 8 to 16 (moderate eczema), 17 to 24 (severe eczema), and 25 to 28 (very severe eczema). Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 19.61 ± 5.307 | 20.53 ± 4.903 |
| Change from baseline at Week 12 | -12.11 ± 7.340 | -14.54 ± 6.761 |
| Change from baseline at Week 16 | -13.00 ± 7.401 | -14.57 ± 6.947 |
| Change from baseline at Week 20 | -11.71 ± 8.888 | -14.51 ± 7.115 |
| Change from baseline at Week 24 | -12.23 ± 10.553 | -14.86 ± 7.208 |
The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | 5.65 ± 1.589 | 12.34 ± 1.066 |
| Change from baseline at Week 4 | 5.84 ± 1.822 | 14.38 ± 1.227 |
| Change from baseline at Week 8 | 4.37 ± 1.761 | 16.48 ± 1.124 |
The EQ-5D is a validated, self-administered, generic utility questionnaire wherein participants rate their current health state based on the following criteria (dimensions): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5L indicates that, for each dimension, there are 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The participant was asked to indicate his/her health state over the past 7 days using a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Missing values were not imputed. Change from Baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 71.09 ± 18.742 | 66.26 ± 20.738 |
| Change from baseline at Week 12 | 5.50 ± 16.169 | 16.93 ± 23.868 |
| Change from baseline at Week 16 | 9.71 ± 16.226 | 19.41 ± 21.764 |
| Change from baseline at Week 20 | 9.14 ± 15.160 | 19.94 ± 21.208 |
| Change from baseline at Week 24 | 10.69 ± 10.696 | 20.69 ± 20.777 |
The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2, Anxiety | -1.01 ± 0.351 | -1.68 ± 0.236 |
| Change from baseline at Week 4, Anxiety | -1.43 ± 0.389 | -1.91 ± 0.262 |
| Change from baseline at Week 8, Anxiety | -1.26 ± 0.417 | -2.25 ± 0.271 |
| Change from baseline at Week 2, Depression | -0.58 ± 0.305 | -1.36 ± 0.205 |
| Change from baseline at Week 4, Depression | -0.61 ± 0.320 | -1.56 ± 0.216 |
| Change from baseline at Week 8, Depression | -0.33 ± 0.370 | -1.82 ± 0.239 |
The HADS is a 14-item questionnaire that assesses the levels of anxiety and depression a person is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question: 0, 1, 2, or 3. Separate scores were calculated for anxiety and depression, both ranging from 0 to 21; a higher score indicates a greater level of anxiety/depression. The recall period was the past 7 days for both the VC and VCE periods. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline, Anxiety | 6.75 ± 4.675 | 6.62 ± 4.628 |
| Change from baseline at Week 12, Anxiety | -2.89 ± 4.536 | -2.61 ± 4.165 |
| Change from baseline at Week 16, Anxiety | -3.14 ± 3.860 | -2.59 ± 4.681 |
| Change from baseline at Week 20, Anxiety | -3.29 ± 3.667 | -2.64 ± 4.516 |
| Change from baseline at Week 24, Anxiety | -3.23 ± 3.898 | -2.78 ± 4.103 |
| Baseline, Depression | 4.10 ± 3.518 | 4.53 ± 4.010 |
| Change from baseline at Week 12, Depression | -0.89 ± 3.234 | -1.95 ± 3.570 |
| Change from baseline at Week 16, Depression | -0.93 ± 3.362 | -2.11 ± 4.124 |
| Change from baseline at Week 20, Depression | -0.93 ± 3.245 | -2.08 ± 4.061 |
| Change from baseline at Week 24, Depression | -1.85 ± 3.460 | -2.18 ± 3.623 |
The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -2.18 ± 0.704 | -4.50 ± 0.474 |
| Change from baseline at Week 4 | -2.78 ± 0.728 | -5.86 ± 0.491 |
| Change from baseline at Week 8 | -2.79 ± 0.778 | -6.25 ± 0.504 |
The PROMIS Short Form - Sleep-Related Impairment (8a) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related impairment. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 21.20 ± 7.628 | 22.03 ± 7.527 |
| Change from baseline at Week 12 | -4.61 ± 7.777 | -6.66 ± 8.139 |
| Change from baseline at Week 16 | -6.93 ± 7.468 | -8.27 ± 8.283 |
| Change from baseline at Week 20 | -4.93 ± 5.850 | -8.48 ± 8.407 |
| Change from baseline at Week 24 | -7.00 ± 7.649 | -8.03 ± 8.317 |
The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Change from baseline at Week 2 | -3.22 ± 0.705 | -5.74 ± 0.474 |
| Change from baseline at Week 4 | -3.16 ± 0.740 | -7.06 ± 0.498 |
| Change from baseline at Week 8 | -3.25 ± 0.847 | -7.00 ± 0.548 |
The PROMIS Short Form - Sleep-Related Disturbance (8b) is an 8-item questionnaire. Each item is rated on a 5-point scale (never, almost never, sometimes, almost always, and always). Individual items are summed to get a total score ranging from 8 to 40; higher scores indicate greater severity of sleep-related disturbance. The recall period was 7 days. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline | 23.65 ± 7.109 | 24.65 ± 7.334 |
| Change from baseline at Week 12 | -5.17 ± 6.688 | -7.93 ± 8.643 |
| Change from baseline at Week 16 | -6.79 ± 6.773 | -8.75 ± 8.703 |
| Change from baseline at Week 20 | -5.36 ± 6.122 | -8.95 ± 8.842 |
| Change from baseline at Week 24 | -6.31 ± 7.123 | -8.79 ± 8.634 |
The WPAI-AD questionnaire is a validated 6-item instrument that measures the effect of overall health and specific symptoms on productivity at work and regular activities outside of it during the past 7 days. The WPAI outcomes are expressed as impairment percentages (0% to 100% for all outcomes; higher number indicate greater impairment and less productivity \[i.e., worse outcomes\]): Questions: 1 = currently employed; 2 = hours missed due to AD; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree AD-affected productivity while working; 6 = degree AD-affected regular activities. Scores: multiply scores by 100 to express in percentages: percent work time missed due to AD: Q2 / (Q2 + Q4); percent impairment while working due to AD: Q5 / 10; percent overall work impairment due to AD: Q2 / (Q2 + Q4) + (\[1 - (Q2 / (Q2+Q4)\] × \[Q5/10\]); percent activity impairment due to AD: Q6 / 10. Change from baseline was calculated as the post-baseline value minus the baseline value.
| scores on a scale | Vehicle Cream | Ruxolitinib 1.5% Cream |
|---|---|---|
| Baseline, Percent work time missed due to AD | 7.55 ± 16.086 | 6.80 ± 16.233 |
| CFB at Week 8, Baseline, Percent work time missed due to AD | -0.91 ± 13.613 | -4.35 ± 16.146 |
| CFB at Week 24, Baseline, Percent work time missed due to AD | 0.00 ± 0.000 | -3.21 ± 19.940 |
| Baseline, Percent impairment while working due to AD | 55.27 ± 21.504 | 46.85 ± 23.855 |
| CFB at Week 8, Percent impairment while working due to AD | -18.75 ± 25.996 | -35.73 ± 26.979 |
| CFB at Week 24, Percent impairment while working due to AD | -44.29 ± 28.785 | -34.67 ± 26.647 |
| Baseline, Percent overall work impairment due to AD | 57.40 ± 22.994 | 49.20 ± 24.325 |
| CFB at Week 8, Percent overall work impairment due to AD | -17.88 ± 26.188 | -36.66 ± 28.341 |
| CFB at Week 24, Percent overall work impairment due to AD | -44.29 ± 28.785 | -34.79 ± 28.271 |
| Baseline, Percent activity impairment due to AD | 56.33 ± 24.399 | 55.07 ± 21.836 |
| CFB at Week 8, Percent activity impairment due to AD | -20.36 ± 31.216 | -43.57 ± 25.958 |
| CFB at Week 24, Percent activity impairment due to AD | -43.08 ± 40.903 | -43.92 ± 26.242 |
Collected over up to approximately 1.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Cream | 1/81 (1.2%) | 1/81 (1.2%) | 12/81 (14.8%) |
| Ruxolitinib 1.5% BID | 0/206 (0%) | 4/206 (1.9%) | 36/206 (17.5%) |
| Event | Vehicle Cream | Ruxolitinib 1.5% BID |
|---|---|---|
| Sudden deathGeneral disorders | 1/81 | 0/206 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/81 | 1/206 |
| HypertensionVascular disorders | 0/81 | 1/206 |
| Radius fractureInjury, poisoning and procedural complications | 0/81 | 1/206 |
| Suicide attemptPsychiatric disorders | 0/81 | 1/206 |
| Event | Vehicle Cream | Ruxolitinib 1.5% BID |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/81 | 24/206 |
| Application site painGeneral disorders | 5/81 | 2/206 |
| NasopharyngitisInfections and infestations | 4/81 | 12/206 |
| Age, Continuous(years) | Vehicle Cream | Ruxolitinib 1.5% Cream | Total |
|---|---|---|---|
| Mean | 39.7 ± 16.33 | 39.0 ± 16.29 | 39.2 ± 16.27 |
| Sex: Female, Male(Participants) | Vehicle Cream | Ruxolitinib 1.5% Cream | Total |
|---|---|---|---|
| Female | 45 | 86 | 131 |
| Male | 36 | 74 | 110 |
| Race/Ethnicity, Customized(Participants) | Vehicle Cream | Ruxolitinib 1.5% Cream | Total |
|---|---|---|---|
| White/Caucasian | 68 | 126 | 194 |
| Black/African-American | 7 | 7 | 14 |
| Asian | 5 | 20 | 25 |
| Native Hawaiian/Pacific Islander | 0 | 1 | 1 |
| Not Reported | 0 | 1 | 1 |
| Phillipino | 0 | 1 | 1 |
| Mix of White and American-Indian | 1 | 0 | 1 |
| Missing | 0 | 4 | 4 |
| Race/Ethnicity, Customized(Participants) | Vehicle Cream | Ruxolitinib 1.5% Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 7 | 9 |
| Not Hispanic or Latino | 78 | 148 | 226 |
| Not Reported | 0 | 1 | 1 |
| Unknown | 1 | 0 | 1 |
| Missing | 0 | 4 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Apr 2024 to primary completion in May 2025, 12 months.
Results were first posted in May 2026, 1 year after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib